Jonathan Kell

3.6k citations
57 papers · 2.5k · 1 hit paper · h-index 20

Impact in

  • Hematology top 0.5%
    • Acute Myeloid Leukemia Research
    • Hematopoietic Stem Cell Transplantation
    • Multiple Myeloma Research and Treatments
  • Genetics top 2%
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

    • Acute Myeloid Leukemia Research 36
    • Multiple Myeloma Research and Treatments 9
    • Retinoids in leukemia and cellular processes 12

Jonathan Kell

56 papers receiving 2.5k citations

Jonathan Kell's Hit Papers

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial 2010 · 491 citations
4910+5+10Years since publication100200300400

Peers

Jonathan Kell
Comparison fields: 5 of 84
  • Hematology 1.8k
  • Genetics 318
  • Public Health, Environmental and Occupational Health 539
  • Oncology 478
  • Biochemistry 101
Replace Lars Möllgård with:
Lars Möllgård Sweden
Kavitha M. Lakshmi India
Åsa Rangert Derolf Sweden
Georgine E. de Greef Netherlands
Susan O’Brien United States
Francesco Nobile Italy
J Treleaven United Kingdom
Z Arlin United States
Musa Yılmaz United States
Éliane Duchayne France
Jonathan Kell relative to Lars Möllgård Sweden Lars Möllgård's profile →
Citations per field
00.5×1.5×
Lars Möllgård · 1×
Citations per year

Countries citing papers authored by Jonathan Kell

Since Specialization
Citations

This map shows the geographic impact of Jonathan Kell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Kell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Kell more than expected).

Fields of papers citing papers by Jonathan Kell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Kell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Kell. The network helps show where Jonathan Kell may publish in the future.

Co-authors

The 25 scholars most cited alongside Jonathan Kell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jonathan Kell Line = papers co-authored together Jonathan Kell links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 57 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Hit paper breakdown →
2010491
2 2015350
3 2012293
4 2015200
5 2006131
6 2010125
7 2006102
8 200871
9 201363
10 200958
11 201657
12 201253
13 201242
14 200938
15 201135
16 200626
17 202022
18 200622
19 202020
20 200420

About Jonathan Kell

Jonathan Kell is a scholar working on Hematology, Molecular Biology, Public Health, Environmental and Occupational Health, Oncology and Genetics, having authored 57 papers that have together received 2.5k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (36 papers), Acute Lymphoblastic Leukemia research (13 papers), Retinoids in leukemia and cellular processes (12 papers), Multiple Myeloma Research and Treatments (9 papers), Cancer survivorship and care (6 papers), HIV/AIDS drug development and treatment (5 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Hematological disorders and diagnostics (4 papers). The work is most often cited by research in Hematology (1.8k citations), Genetics (318 citations), Public Health, Environmental and Occupational Health (539 citations), Oncology (478 citations) and Biochemistry (101 citations). Jonathan Kell has collaborated with scholars based in United Kingdom, United States and Denmark. Frequent co-authors include Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Keith Wheatley, Lars Kjeldsen, Donald Milligan, Ann Hunter, Anthony H. Goldstone, John A. Liu Yin and David Grimwade. Their work appears in journals such as Blood, British Journal of Haematology, Journal of Clinical Oncology, Leukemia and Leukemia Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact